While the combination of VSV and recombinant Flt3L improved animal survival (30% cured animals), the VSV-based expression of Flt3L did not provide a significant treatment advantage in B16 melanoma, and only modest improved survival in the E.G7 model. The gene discussed is FLT3LG; the disease is melanoma.